Cannabis rescheduling is partial, and as of mid-October 2026 it is still moving, so a communications plan has to be precise about what has changed and what has not. In April 2026 the federal government moved FDA-approved marijuana products and marijuana under a state medical license to Schedule III. Adult-use marijuana remains in Schedule I, and a broader proceeding is pending. A brand that says "marijuana has been rescheduled" without that detail is making a claim that is wrong for most of the market.

What would I tell a cannabis operator this week?

I would tell an operator not to announce anything it cannot source to a dated primary document. Rescheduling headlines compress a two-tier rule into one phrase, and the brand that repeats the phrase owns the error. The safer move is to publish a short, dated status note on your own site and update it when the facts change.

I checked the status below on October 16, 2026 against the DEA's October 14 order. It will probably move again before this page is read, so confirm the current status before you quote any date.

What has actually changed in federal cannabis policy?

What has changed is a two-tier federal framework: certain medical and FDA-approved products are now in Schedule III, and everything else remains in Schedule I. The dates below come from published legal and government summaries and should be checked against the primary sources before anyone relies on them.

  • December 18, 2025: President Donald Trump signed an executive order directing the attorney general to reschedule marijuana from Schedule I to Schedule III, according to a summary from the law firm Ogletree.
  • April 22, 2026: Acting Attorney General Todd Blanche signed a final order moving FDA-approved marijuana products and marijuana subject to a state medical marijuana license to Schedule III, effective immediately, according to law-firm summaries. The DEA published the final rule in the Federal Register on April 28, 2026.
  • What stayed in Schedule I: All other marijuana, including adult-use marijuana, remained in Schedule I. The order also does not affect hemp, which is defined separately, and synthetic THC stays in Schedule I, according to the Federal Register notice.
  • June 29, 2026: A new DEA administrative hearing began to consider broader rescheduling of all marijuana to Schedule III.
  • September 29, 2026: The DEA's chief administrative law judge paused the proceeding to consider whether to admit a new Government Accountability Office report, with agency responses due October 13, according to Ogletree.
  • October 9 to 14, 2026: According to the judge's October 14 order, the government opposed adding the report on October 9, and parties who sought the pause filed motions on October 12, including one to reopen the hearing for limited discovery and testimony if the report is admitted. The judge reserved ruling on admitting the report and set October 21, 2026 as the date for responses to the motion to reopen.

Law-firm commentary describes the pause as procedural and not a rejection of rescheduling, and notes that the GAO report examines agency procedures and does not recommend against rescheduling. A recommendation from the judge would not be a final decision either. I would treat the broader outcome as open.

The details here change quickly. Anyone using this article should check the current status of the proceeding before making a public statement.

What has not changed?

Federal law still treats most marijuana as a Schedule I drug, and rescheduling is not legalization. A policy group's explainer quotes the government's own order as saying that any form of marijuana remains generally illegal under federal law outside the specific categories moved. Rescheduling to Schedule III does not release anyone incarcerated for marijuana and does not restore rights lost through past convictions, according to that same explainer.

For a communications team, the practical points are these. Adult-use operators did not receive the relief that medical licensees did. State laws still govern state markets. And even for qualifying medical licensees, federal registration, recordkeeping and security requirements now apply under the Schedule III framework, according to the law-firm alerts.

Why does precise language matter so much?

Precise language matters because the gap between what rescheduling does and what people think it does is where most of the risk sits. Headlines compress a two-tier rule into a single phrase, and a brand that repeats the phrase inherits the error.

My advice is to build a short glossary and enforce it across every channel. Use "rescheduled" only for the categories that were rescheduled. Use "medical" and "adult-use" as distinct terms. Avoid the word "legal" unless you mean legal under a specific state law. Avoid any phrase that implies federal approval of products that were not approved. A press release, a social post and a founder's interview should all use the same terms.

This matters for regulators as well as readers. Claims that overstate a product's legal status can draw attention from licensing bodies and from platforms that enforce their own rules.

How should a cannabis company message to different audiences?

A cannabis company should message separately to five audiences, because each one reads the news differently: customers, investors, employees, regulators and the press. The same facts, framed differently, avoid confusion.

  • Customers: Say what has not changed for them. A customer in an adult-use state still buys under state law, and the product's status has not been transformed by the April order. Clear, short language avoids false expectations.
  • Investors: Distinguish what is in force from what is pending. Describe scenarios, not predictions. Avoid forward-looking statements that the company cannot support, and involve counsel in anything that could be read as a financial claim.
  • Employees: Explain how the news affects their work and licenses, and what the company will tell them as things change. Staff are asked about this by friends and family, so they need a consistent answer.
  • Regulators and partners: Be accurate and conservative. A statement to a licensing body or a bank should match what the company says in public.
  • The press: Offer facts, dates and a knowledgeable spokesperson. Reporters will ask what changes for the business, and "it depends on the outcome of a pending proceeding" is an honest answer.

What should a company say about taxes and money?

A company should say as little as possible about tax benefits until a qualified adviser has reviewed the statement. The law-firm summary of the April order describes the elimination of the Section 280E tax deduction disallowance going forward for qualifying medical licensees, but another compliance analysis cautions against booking any tax benefit until a final rule is complete, because Section 280E applies to Schedule I and Schedule II substances and the broader proceeding is not finished.

Those two readings differ in scope, which is itself a reason for caution. A public statement that promises tax savings can become a liability if the facts change or if the company's own situation does not qualify. Tax claims belong with the company's tax advisers, and a communications plan should route any question on the topic to them.

How does advertising change the PR job?

Advertising limits mean earned media still carries much of the load for cannabis brands, and rescheduling does not remove those limits. Paid channels and platforms continue to restrict cannabis promotion in many places, and the rules are separate from the federal scheduling decision. A broader description of how earned media works in the sector is in the cannabis public relations guide, and the wider category is covered by the cannabis pillar.

The result is that the news cycle around rescheduling is an opportunity for credible, careful commentary. A brand that explains what the change means for patients, operators or the supply chain, without hype, builds authority. A brand that celebrates a legalization that has not happened loses credibility.

What is the hemp deadline, and why mention it?

The hemp deadline matters because a separate federal change affects many cannabis-adjacent brands on a fixed date. A compliance analysis published in early October says that a narrower federal definition of hemp in P.L. 119-37 section 781 takes effect on November 12, 2026 by statute, and that the Senate voted 90 to 6 to move the date to December 11 while the House had not acted. That source describes November 12 as the operative date for now. Verify this date again before publishing, since Congress could still act.

I mention it because it is a communications issue as much as a legal one. Brands selling hemp-derived products will need a plan for customers, retailers and the press if their products are affected. The deadline is a known date, so the messages can be drafted in advance. The lesson from earlier research on this site, such as the CBD citation share study, is that categories with restricted advertising depend on independent sources for visibility, and those sources reward clear, sourced facts.

How should a team plan for the possible outcomes?

A team should plan for three outcomes and draft messages for each before any decision arrives: the proceeding resumes and produces a recommendation, it is delayed again, or it ends with no broader change. The plan does not need to predict which will happen. It needs to be ready.

  1. Draft the facts: One page stating what is in force, what is pending and the dates, updated whenever the status changes.
  2. Draft the messages: A short statement for each outcome, reviewed by counsel, for customers, investors, employees and the press.
  3. Name the spokespeople: Decide who speaks, who approves and how quickly the team can respond when news breaks.
  4. Set a review rhythm: Check official sources and trusted legal summaries weekly, and after any filing date such as the October 21 response date.
  5. Prepare for backlash: Some audiences will react strongly to either result. A calm, factual reply is better than a defensive one. The crisis communications hub covers the structure.

How do AI engines describe cannabis rescheduling?

AI engines describe it from whatever sources they find, and the sources are mixed, dated and sometimes wrong. Many consumers now ask an engine whether marijuana is legal or rescheduled, and the answer may be out of date or may blur the medical and adult-use tiers. Brands can help by publishing clear, dated explanations on their own sites that state the current status and the sources, and by earning coverage in credible outlets. The method for checking what engines say is in the AI visibility guide, and an earlier study on this site, pre-legalization AI visibility, shows how engines answer questions about categories whose legal status is in flux.

Where does this fit in a wider program?

Rescheduling is one news event inside a continuing program of reputation, media and crisis readiness. For the media side, see media relations, and for the full set of sector guides, see the industry PR guides.

Cannabis and wellness brands that want help with communications planning can look at 5W's cannabis PR and digital marketing practice.

Frequently asked questions

Is marijuana rescheduled?

Partly. In April 2026 a federal order moved FDA-approved marijuana products and marijuana under a state medical license to Schedule III. Adult-use marijuana remains in Schedule I, and a broader proceeding is pending.

Is marijuana now federally legal?

No. Rescheduling is not legalization. Marijuana outside the rescheduled categories remains a Schedule I substance under federal law.

What is the latest in the DEA proceeding?

As of the judge's October 14, 2026 order, the judge had not yet ruled on whether to admit the GAO report, and responses to a motion to reopen the hearing were due October 21. Check the DEA docket and current legal summaries for what happened next.

What should a cannabis brand avoid saying?

Avoid saying that marijuana is "legal" or "rescheduled" without specifying the category and jurisdiction, and avoid promising tax or financial benefits without advice from qualified advisers.

Is this legal advice?

No. This is a communications guide based on published summaries. A cannabis business should consult its lawyers and tax advisers on its own situation.